Evelo Biosciences Revenue and Competitors
Estimated Revenue & Valuation
- Evelo Biosciences's estimated annual revenue is currently $27M per year.
- Evelo Biosciences's estimated revenue per employee is $599,333
- Evelo Biosciences's total funding is $281.5M.
- Evelo Biosciences's current valuation is $295.1M. (January 2022)
Employee Data
- Evelo Biosciences has 45 Employees.
- Evelo Biosciences grew their employee count by -62% last year.
Evelo Biosciences's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Financial Officer | Reveal Email/Phone |
2 | CSO | Reveal Email/Phone |
3 | CEO | Reveal Email/Phone |
4 | VP, Program and Vendor Management | Reveal Email/Phone |
5 | SVP, Head Research | Reveal Email/Phone |
6 | VP, Intellectual Property | Reveal Email/Phone |
7 | VP, Head Corporate Development and Strategic Integration | Reveal Email/Phone |
8 | Director Statistics | Reveal Email/Phone |
9 | Director, In Vivo Pharmacology | Reveal Email/Phone |
10 | Chief Technology & Quality Officer | Reveal Email/Phone |
Evelo Biosciences Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Evelo Biosciences?
Evelo Biosciences, Inc. is a clinical stage biotechnology company developing oral biologics that act on cells in the small intestine with systemic therapeutic effects. These cells in the small intestine play a central role in governing the immune, metabolic and neurological systems. The company?s first product candidates are monoclonal microbials, single strains of microbes selected for defined pharmacological properties. They have been observed in preclinical models to have systemic dose-dependent effects, modulating multiple clinically validated pathways. Evelo?s therapies have the potential to be effective, safe and affordable medicines to improve the lives of people with chronic disease and cancer. Evelo currently has three product candidates, EDP1066 and EDP1815 for the treatment of inflammatory diseases and EDP1503 for the treatment of cancer. Evelo is also advancing additional oral biologics through preclinical development in other disease areas.
keywords:N/A
$281.5M
Total Funding
45
Number of Employees
$27M
Revenue (est)
-62%
Employee Growth %
$295.1M
Valuation
N/A
Accelerator
Evelo Biosciences News
On average, analysts give Evelo Biosciences Inc a Strong Buy rating. The average price target is $19.1, which means analysts expect the stock to...
Evelo Biosciences is a clinical stage biotechnology company developing orally delivered product candidates that are designed to act on the small...
Evelo Biosciences is a clinical stage biotechnology company developing orally delivered product candidates that are designed to act on the small...
CAMBRIDGE, Mass., July 25, 2019 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a biotechnology company developing oral biologics that act on cells in the small intestine with systemic therapeutic effects, today announced that it has entered into a loan and security agreement for up ...
Simba Gill With its lead “monoclonal microbial” about to be tested for the first time on a human, Evelo Biosciences believes that this is the right time to float a $100 million IPO. Launched with $85.4 million raised from the sale of stock to Flagship and a loan from Pacific Wes ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $7.6M | 45 | -6% | $128.2M |
#2 | $3.5M | 45 | 18% | N/A |
#3 | $12.7M | 45 | -18% | N/A |
#4 | $3.7M | 45 | 18% | N/A |
#5 | $9M | 45 | -13% | N/A |